Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
View Scopus Profile
Ling Li
Instructor
School of Medicine
2014
2024
Research activity per year
Overview
Fingerprint
Network
Research output
(33)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Ling Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Liver Cell Carcinoma
85%
Crohn's Disease
82%
Anus Fistula
67%
Combination Therapy
46%
Bile Duct Carcinoma
44%
Rat Model
44%
Bortezomib
41%
microRNA
41%
Nanofiber
41%
Nanoparticle
38%
Fistula
38%
Tissue Repair
36%
Disease
34%
Drug Screening
31%
Sustained Release
31%
Neoplasm
25%
Porcine Model
23%
Mouse Model
23%
Systemic Circulation
23%
Gene Delivery
20%
Inflammatory Bowel Disease
20%
Irritable Colon
20%
Insulin Resistance
20%
Infectious Agent
20%
Protein Synthesis Inhibitor
20%
Fatty Liver
20%
Nonalcoholic Fatty Liver
20%
Fibrosis
20%
Synapsin II
20%
Helicobacter Pylori
20%
Stomach Cancer
20%
Drug Release
20%
Inflammasome
20%
Nucleotide Binding Oligomerization Domain Like Receptor
20%
Pyrin
20%
Biomaterial
20%
Inflammation
14%
Biological Product
13%
Sulconazole
12%
Liver Cancer
11%
Elimination
10%
Ketorolac Trometamol
10%
Analgesic Agent
10%
Antibiotics
10%
Immunomodulating Agent
10%
Remission
10%
Janus Kinase Inhibitor
10%
Adhesive Agent
10%
Tumor Microenvironment
8%
Medicine and Dentistry
Organoid
73%
microRNA
61%
Neoplasm
61%
Liver Cancer
46%
Cholangiocarcinoma
43%
Hepatocellular Carcinoma
43%
Stricture
41%
Severe Acute Respiratory Syndrome Coronavirus 2
41%
Autopsy
41%
Crohn's Disease
41%
Seroprevalence
34%
Fistula
29%
Hepatobiliary Cancer
28%
Fibrosis
27%
Combination Therapy
27%
COVID-19
26%
Anal Fistula
26%
Malignant Neoplasm
25%
Drug Screening
23%
Personalized Medicine
20%
Drug Response
20%
Gastroplasty
20%
Fatty Liver
20%
Bile
20%
Synapsin II
20%
Exosome
20%
Pyrin Domain
20%
Prospective Cohort Study
20%
Nonviral Gene Delivery System
20%
Body Weight
20%
Nonalcoholic Fatty Liver
20%
Intraarterial Drug Administration
20%
Stomach Cancer
20%
Helicobacter Pylori
20%
Insulin Resistance
20%
Mucosa
20%
Alzheimer's Disease
20%
TAR DNA Binding Protein
20%
Inflammasome
20%
Nucleotide Binding Oligomerization Domain Like Receptor
20%
Bortezomib
20%
Tissue Degeneration
20%
Nanofiber
20%
Nanoparticle
18%
Infection
15%
Cancer Associated Fibroblast
14%
Sulconazole
12%
Hydrodynamics Based Transfection
12%
Genetic Transfection
11%
Amino Esters
11%
Keyphrases
Cholangiocarcinoma
41%
Bortezomib
41%
Patient-derived Organoids
35%
Liver Cancer
23%
Hepatocellular Carcinoma
23%
Sustained Release
20%
Establishment Limitation
20%
INTS6
20%
Stricture
20%
Combination Therapy
20%
Rat Model
20%
Exosome microRNAs
20%
MicroRNA-335
20%
Extracellular Vesicles
20%
Gastrointestinal
20%
CXCR4 Inhibitor
20%
Hepatobiliary Cancer
20%
Human Bile
20%
Nanofiber-hydrogel Composites
20%
Patient-derived
20%
Shape-changing Devices
20%
MicroRNA-195
20%
Swine Model
20%
Cancer Organoids
20%
CY-09
20%
Personalized Approach
20%
Crohn's Disease
20%
Drug Screening
20%
Checkpoint Inhibitors
20%
MicroRNA-224
20%
Nanoparticles
20%
Tissue Repair
20%
MiR-490-3p
20%
Organoids
20%
Omacetaxine
20%
Biostimulatory
20%
MicroRNA
20%
Perianal Fistula
20%
Forensic
20%
Antibody Status
20%
COVID-19
20%
Decedents
20%
Pandemic Surveillance
20%
Maryland
20%
Postmortem Examination
20%
Complex Patients
15%
Hydrodynamic Delivery
13%
Cancer-associated Fibroblasts
12%
C-X-C Chemokine Receptor Type 4 (CXCR4)
12%
Self-latching
10%